Second primary malignancies (SPMs) represent a small proportion of adverse events (AEs) reported by patients receiving chimeric antigen receptor T-cell (CAR T-cell) therapy, according to a letter to the editor published online ...
Mar 20, 2024
0
0
Implementing the International Prognostic Scoring System-Molecular (IPSS-M) in clinical practice could impact clinical management for nearly half of patients with myelodysplastic syndromes (MDS), according to a study published ...
Jun 16, 2023
0
2
(HealthDay)—Among older patients with myelodysplastic syndrome (MDS), survival rates are better for those undergoing allogeneic hematopoietic cell transplantation (HCT), according to a study presented at the annual meeting ...
Dec 8, 2020
0
0
In Spain, a workgroup of more than 400 researchers—the Spanish Group of Myelodysplastic Syndromes (GESMD)—meets twice a year to present projects and undertake collaborations that improve their work in the fight against ...
Nov 4, 2019
0
0
Researchers from King's College have led research that has resulted in the publication of first-of-their-kind guidelines that seek to standardize how clinicians measure the immune response of patients who have myelodysplastic ...
Jul 12, 2024
0
0
Maria Creignou from the Hematology Unit (HERM) at the Department of Medicine, Huddinge (MedH) is defending her thesis: "Improving prognostication for patients with myelodysplastic syndromes" on 27 October 2023. Her main supervisor ...
Oct 23, 2023
0
0
It's possible to postpone the introduction of blood transfusions for an average of 17 months for patients with the low-risk variant of MDS blood cancer, provided they are given erythropoiesis-stimulating agents (ESA), which ...
Sep 24, 2018
0
0
